Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 546-555

  Baretton, G B ^a   Klenk, U ^a   Diebold, J ^a   Schmeller, N ^b   Lohrs U ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Androgen independence; Apoptosis; p21 WAF1 CIP1 immunohistochemistry; Prognosis; Proliferation; Prostate cancer pathology

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BUSERELIN ACETATE; CISPLATIN; CYPROTERONE ACETATE; DNA FRAGMENT; EPIRUBICIN; ESTRAMUSTINE; FLUTAMIDE; FOSFESTROL; GOSERELIN; KI 67 ANTIGEN; LEUPRORELIN; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER REGRESSION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; APOPTOSIS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, NEOPLASM; GROWTH SUBSTANCES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032927729     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690390     Document Type: Article

References (52)

1. Ansari B, Coates PJ, Greenstein BD and Hall PA (1993) In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170: 1-8
2. Blagosklonny MV, Prabhu NS and El-Deiry WS (1997) Defects in P21/WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 57: 320-325
3. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F and Allred DC (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369-3373
4. Breslow NE and Day NE (1980) The Analysis of Case Control Studies. IARC Scientific Publications, no. 32. IARC: Lyon
5. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC and Mihatsch MJ (1996) Prognostic significance of Bcl-2 in clinically localised prostate cancer. Am J Pathol 148: 1557-1565
6. Chen X, Bargonetti J and Prives C (1995) p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. Cancer Res 55: 4257-4263
7. Civantos F, Marcial MA, Banks ER, Ho CK, Speights VO, Drew PA, Murphy WM and Soloway MS (1995) Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients. Cancer 75: 1634-1641
8. Colombel M, Symmons F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S and Buttyan R (1993) Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143: 390-400
9. Eastham JA, Stapleton AMF, Gousse AE, Timme TL, Yang G, Slawin KM, Wheeler TM, Scardino PT and Thompson TC (1995) Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1: 1111-1118
10. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW and Vogelstein B (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174
11. Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE and Dowsett M (1997) Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer 76: 480-485
12. Erber R, Klein W, Andl T, Enders C, Born AI, Conradt C, Bartek J and Bosch FX (1998) Aberrant p21 (CIP1/WAF1) protein accumulation in head-and-neck cancer. Int J Cancer 74: 383-389
13. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H and Brooks M (1992) Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128
14. Gao X, Chen YQ, Wu N, Grignon DJ, Sakr W, Porter AT and Honn KV (1995) Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11: 1395-1398
15. Gavrieli Y, Sherman Y and Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501
16. Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273-279
17. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125-128
18. Gleason DF and Mellinger GI (1974) Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 111: 58-64
19. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, Kaibara N and Ito H (1997) Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79: 2067-2072
20. Harada N, Gansauge S, Gansauge F, Gause H, Shimoyama S, Imaizumi T, Mattfeld T, Schoenberg MH and Beger HG (1997) Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) in pancreatic cancer. Br J Cancer 76: 299-305
21. Hollander M and Wolfe DA (1973) Non-parametric Statistical Methods. Wiley and Sons: New York.
22. Hölzel D, Klamert A and Schmidt M (1996) Krebs: Häufigkeiten, Befunde und Behandlungsergehnisse. Perspektiven für die Krebsdiskussion und eine quantitative klinisch-epidemiologische Onkologie aus dem Tumorregister München. W Zucker Schwerdt Verlag: Munich
23. Huggins C and Hodges CV (1941) Studies on prostatic cancer I. Cancer Res 1: 293-297
24. Isaacs JT, Furuya Y and Berges R (1994) The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5: 391-400
25. Klocker H, Culig Z, Hobisch A, Cato AC and Bartsch G (1994) Androgen receptor alterations in prostatic carcinoma. Prostate 25: 266-273
26. Korsmeyer SJ (1992a) bcl-2: a repressor of lymphocyte death. Immunol Today 13: 285-287
27. Korsmeyer SJ (1992b) bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886
28. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC (1996) Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567-1576
29. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y and Danenberg K (1995) Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 27: 18-24
30. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
31. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453
32. Li Y, Jenkins CW, Nichols MA and Xiong Y (1994) Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9: 2261-2268
33. Lukas J, Groshen S, Saffari B, Niu N, Reles A, Wen WH, Felix J, Jones LA, Hall FL and Press MF (1997) WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 150: 167-175
34. Maelandsmo GM, Holm R, Fodstad O, Kerbel RS and Florenes VA (1997) Cyclin kinase inhibitor p21/WAF1/CIP1 in malignant melanoma. Reduced expression in metastatic lesions. Am J Pathol 149: 1813-1822
35. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-R, Tu S-M and Campbell ML (1992) Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52: 6940-6944
36. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D (1994) Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395
37. Miyamoto KK, McSherry SA, Dent GA, Sar M, Wilson EM, French FS, Sharief Y and Mohler JL (1993) Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 149: 1015-1019
38. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC and Conti CJ (1993) p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669
39. Peterziel H, Culig Z, Stober J, Hobisch A, Radmayr C, Bartsch G, Klocker H and Cato AC (1995) Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding. Int J Cancer 63: 544-550
40. Piffko J, Bankfalvi A, Öfner D, Joos U, Böcker W and Schmid KW (1995) Immunohistochemical detection of p53 protein in archival tissues from squamous cell carcinomas of the oral cavity using wet autoclave antigen retrieval. J Pathol 176: 69-75
41. Polyak K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389: 300-305
42. Shurbaji MS, Kalbfleisch JH and Thurmond TS (1995) Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 26: 106-109
43. Stewart BW (1994) Mechanisms of apoptosis: Intergration of genetíc, biochemical, and cellular indicators. J Natl Cancer Inst 86: 1286-1296
44. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S and Shimazaki J (1996) Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29: 153-158
45. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN and Balk SP (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398
46. Trapman J and Brinkmann AO (1996) The androgen receptor in prostate cancer. Pathol Res Pract 192: 752-760
47. Trotter MJ, Tang L and Tron VA (1997) Overexpression of the cyclín-dependent kinase inhibitor 21 (WAF1/CIP1) in human cutaneous malignant melanoma. J Cutan Pathol 24: 265-271
48. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T and Isola J (1992) Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84: 883-887
49. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J and Kallioniemi OP (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401-406
50. Wang A, Yoshimi N, Tanaka T and Mori H. (1997) WAF1 expression and p53 mutations in human colorectal cancers. J Cancer Res Clin Oncol 123: 118-123
51. Wentz IE, Deitch AD, Gumerlock PH, Gandour Edwards R, Chi SG and de Vere White RW (1996) Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 27: 573-580
52. Westin P, Stattin P, Damber JE and Bergh A (1995) Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146: 1368-1375